FDA Approves New Therapies For NSCLC and SCLC

FDA Approves New Therapies For NSCLC and SCLC

On December 4, 2024, the FDA announced two significant approvals in lung cancer treatment, including zenocutuzumab-zbco for non-small cell lung cancer (NSCLC) and durvalumab for limited-stage small cell lung cancer (SCLC), marking significant advances in the fight...